| Dr Alexander Howard Peck, PHARMD | |
|
112 N 7th St, Chambersburg, PA 17201-1700 | |
| (717) 264-7195 | |
| Not Available |
| Full Name | Dr Alexander Howard Peck |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 112 N 7th St, Chambersburg, Pennsylvania |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124628847 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | RP448640 (Pennsylvania) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Alexander Howard Peck, PHARMD 112 N 7th St, Chambersburg, PA 17201-1700 Ph: (717) 264-1191 | Dr Alexander Howard Peck, PHARMD 112 N 7th St, Chambersburg, PA 17201-1700 Ph: (717) 264-7195 |
News Archive
CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced it has decided based upon recent developments to primarily focus on the commercialization of Neutrolin in Europe.
Genentech, Inc. a wholly-owned member of the Roche Group, and Biogen Idec announced today that the companies received a Complete Response from the U.S. Food and Drug Administration (FDA) for a supplemental Biologics License Application (sBLA) for Rituxan (rituximab) plus methotrexate (MTX) in patients with moderately-to-severely active rheumatoid arthritis (RA) who no longer respond to treatment with a disease modifying antirheumatic drug (DMARD), including MTX.
A higher body mass index (BMI) increases the risk of developing 10 of the most common cancers, the largest study of its kind on BMI and cancer, involving more than 5 million adults in the UK, published in The Lancet shows.
Results of the randomized, phase III, EORTC/GIMEMA 06012 intergroup trial (AML-17) reported in the Journal of Clinical Oncology show that sequential combination of gemtuzumab ozogamicin (GO) and standard chemotherapy provides no benefit for older patients with acute myeloid leukemia (AML) and is too toxic for patients 70 years of age or more. GO is an antibody-drug conjugate comprised of an anti-CD33 monoclonal antibody linked to a cytotoxic agent.
› Verified 5 days ago
Dr. Richard Collier, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 278 Lincoln Way E, Chambersburg, PA 17201 Phone: 717-263-0747 | |
Miss Abigail Violet Hopple, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1056 Wayne Ave, Chambersburg, PA 17201 Phone: 717-261-2574 | |
Mr. Matthew Howard Folk, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 949 Lincoln Way E, Chambersburg, PA 17201 Phone: 717-261-1303 Fax: 717-261-5915 | |
Dr. Janelle E Phillips, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 913 Norland Ave, T-2241, Chambersburg, PA 17201 Phone: 717-709-2060 | |
Audrey Ellen Klein, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 125 W Washington St, Chambersburg, PA 17201 Phone: 717-263-9893 | |
Melissa Pantano, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 112 N 7th St, Chambersburg, PA 17201 Phone: 717-267-3000 |